Abstract 98P
Background
Lung cancer represents the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for ∼85% of total cases. Although immunotherapy using immune checkpoint inhibitors (ICI) has shown promising results, only a subset of patients benefits from it and there is an urgent need for reliable predictive response biomarkers. Furthermore, traditional tissue biopsies are limited in size and provide a biased representation of the tumour. Therefore, we aimed to explore the possibility to obtain predictive biomarkers of response to ICI in a non-invasive way using liquid biopsy (LB).
Methods
To counter this, we analysed samples from 25 patients from advanced NSCLC treated with pembrolizumab at first line. Blood and tissue samples were collected at baseline to obtain cell-free DNA (cfDNA) and genomic DNA from plasma and PBMCs respectively, and tumour DNA from FFPE primary tumour. All samples underwent a target NGS panel to call somatic mutations in circulating tumour DNA (ctDNA) and primary tumour, evaluating their potential as predictive biomarkers.
Results
Through the integration of three different bioinformatic approaches for variant calling and ROC curve analysis, we identified mutations in key cancer-related genes associated with a 3-month radiological response. We also assessed a promising mutational signature in ctDNA comprising 10 genes with a high ability to predict response to ICI (AUC = 0.98). Although we explored copy number alterations and tumour mutational burden in LB, results did not yield statistical significance, suggesting that assessment of point mutations in particular genes and the proposed signature hold higher potential as biomarkers. Moreover, we compared ctDNA analysis with tissue biopsies, revealing a high concordance between ctDNA and primary tumour, enhancing the reliability of ctDNA analysis as a good alternative for tumour assessment.
Conclusions
These findings highlight the value of ctDNA analysis as a non-invasive predictive biomarker for ICI response and its correlation with mutations found in primary tumours. We also proposed a mutational signature to predict response at baseline for advanced NSCLC ICI treated patients, which could be readily implemented in the clinical management of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Translational Molecular Oncology Unit. IIS Galicia Sur.
Funding
Vigo Contra el Cáncer; GAIN; Xunta de Galicia (ED481A-2020/214); Miguel Servet program (CP20/00188).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract